This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Inclusion Criteria: Age • Male or female patient must be 30 to 75 years of age inclusive, at the time of signing the informed consent form (ICF). Type of Patient and Disease Characteristics * Diagnosis of PD between past 4 to 20 years (meet MDS 2015 clinical diagnostic criteria for PD). * H-Y staging (Appendix III) for "OFF" episodes is 2.5-4.0. * MDS-UPDRS-III score \> 35, and positive for the Acute levodopa challenge test (ALCT) (improvement \> 30% for MDS UPDRS-III staging from OFF episodes to ON episodes) over two screening period visits. Baseline scores will be computed as the means of two screening period visits. * No significant change in UPDRS-III scores between the two visits during the screening period. * Patients who take stable doing of dopamine drug for at least 4 weeks prior to receiving the study drug. * No significant change in dose and dosing schedule of the prescribed medicines for PD during the screening period. * Medically suitable for neurosurgery under general anesthesia. * Acceptable laboratory test values during screening and prior to transplantation (Day 0): * Absolute neutrophil count ≥ 2.0 × 109/L * White blood cell count ≥ 4.0 × 109/L * Platelet count ≥ 100 × 109/L * Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) * Total bilirubin ≤ 1.5 x ULN * Serum creatinine ≤ 1.5 x ULN * eGFR ≥ 50 mL/min/1.73 m2 * Agree to postpone any additional neurosurgical procedures, including DBS, unt…